about
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase IAminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferationTherapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTIncreased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortClinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric populationHIV-1 protease inhibitors in development.New advances in HIV entry inhibitors development.An update in the development of HIV entry inhibitors.Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.Tipranavir in the protease inhibitors arena.Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy.Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol.Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.CD4 cell counts at the third month of HAART may predict clinical failure.Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010.Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus.Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.Description of a "trans-Saharan" strain of human T-lymphotropic virus type 1 in West Africa.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
P50
Q27643872-F240FCF7-C723-450E-9EEA-B61ABB7475DEQ28369300-4A013CF0-7101-4AA9-9BD9-C5983FC4B8BCQ28476094-23B8D87A-7A69-460D-BAEB-80A7DC2FA816Q31020119-B0774085-AD2B-40AA-B287-E61A8C18B095Q31110946-59E40D18-6494-4BCB-BF22-FC9BA703F668Q33768015-2FB87DC7-F30D-492E-BCE6-7DEB157EA832Q33817410-C46ED02D-3762-4A1E-809A-7F54B787CAC2Q34367468-881E8296-E9D8-4472-ABEE-A72145942D67Q34544671-842DF10C-C567-4727-A924-9F9A55D67A16Q35972076-3FFFA7B1-FA6D-456B-B054-68ABC864E47FQ36879432-3FDE284C-0166-4731-A766-DF98BB6F8E9DQ36900555-AF668A63-FD24-4D8B-8938-B83D68C408E1Q37017832-CAF8C260-5AB6-47AB-B6F0-93A2BE281988Q37308894-B4A5B152-32FF-4A68-A41A-25CF5FD989E1Q37500009-9CE97F9E-E75F-48E4-B95F-0CFCF2D17B0BQ37963591-6A80B99E-398A-42DF-A882-C01E46393D77Q38832479-2C8418C3-985C-48E6-BD11-3469B2D4732EQ38914195-E2A00EC3-CCA9-4832-AF05-7D27145A1813Q38915213-B052317F-F1BD-42ED-9AEB-12DAD28022D2Q38925437-54BC42CB-C096-4CCD-AE65-B3EB2FF50381Q38931487-E5BE7D9D-1CC1-47B1-8547-71DC257EA777Q38934042-34B3AAEB-3CC8-4F19-94C8-F5B69B047EF9Q38959222-62455339-6718-444C-9170-B10011751D8BQ38972095-3789B4E4-51A6-40D4-BA6E-9F4C11E45539Q38972140-46436CF6-3FD9-44C2-BD13-00503A1C49A9Q39015984-66F907C5-5660-40D9-B5DA-402B977FC4B3Q39203030-71524659-EF3A-4A09-85B4-3CA6204F9257Q39261456-76221611-39E4-491B-A0DB-C3F0BEA37199Q39414446-4A75460D-C589-49AE-A8FF-AA70F2F35A60Q39425715-B9E9FAF9-96A7-4883-9D21-DEC54B40D0E4Q39463811-0862A32A-5BBF-48B3-9F34-5FCECE0B76FAQ39473811-AF7BF99C-86F4-48BF-A3C5-7681C06AD4CFQ39497261-1907BB30-3F8A-4C3C-9341-7382E22314A7Q39512497-C172E19B-05F6-42EE-8908-DCB2F55F87C3Q39539977-3028B902-9FE7-4383-9903-3D4512BC3620Q39623728-26748E8A-9393-4CCF-8638-8BA52C3A3B46Q40100018-FD057C55-993E-4E10-9CC3-3C87DE108CE5Q40212933-17460EBA-6265-4B9A-BE74-299176D056D5Q40375080-BBE43DCE-C037-4B71-B6D3-356743B8C557Q40404290-9712E1FF-47FE-4D7A-9FFE-4FD3F94F7D25
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefano Rusconi
@ast
Stefano Rusconi
@en
Stefano Rusconi
@es
Stefano Rusconi
@fr
Stefano Rusconi
@sl
type
label
Stefano Rusconi
@ast
Stefano Rusconi
@en
Stefano Rusconi
@es
Stefano Rusconi
@fr
Stefano Rusconi
@sl
prefLabel
Stefano Rusconi
@ast
Stefano Rusconi
@en
Stefano Rusconi
@es
Stefano Rusconi
@fr
Stefano Rusconi
@sl
P1053
H-9263-2012
P106
P1153
7005846988
P21
P31
P3829
P496
0000-0002-0375-9990